Patients Autoimmune Disorders
The immune system is important for defending us against infectious microbes and environmental toxins that could be potentially harmful. This surveillance is carried out mostly by white blood cells called lymphocytes, which recognize foreign antigens and either attack them directly or produce antibodies against them. However, autoimmune diseases can arise when the immune system malfunctions and forms “self-antibodies” (auto-antibodies) that attack normal, healthy tissues in the body.
There are two general types of autoimmune disease: organ-specific, where the autoantibodies attack a specific organ, and systemic, where multiple organ systems are involved. An example of an organ-specific autoimmune disease is Hashimoto’s thyroiditis, in which autoantibodies damage the thyroid gland. On the other hand, in systemic lupus erythematosus (SLE), autoantibodies attack and cause inflammation in many organs, including the skin, joints, and kidneys.
Why our immune system malfunctions is not completely understood. It is thought that genetic susceptibility and a triggering event (e.g., a virus or a change in hormonal balance) together initiate production of autoantibodies that over time create clinical symptoms (this process can take several years). The development of autoimmune disease is a multifactorial process involving immune system derailment that is often triggered by and imbalanced intestinal flora and damage to the gut lining.
The upregulated immune response and inflammation cycle characteristic of autoimmune diseases can cause chronic tissue damage over time. Systemic autoimmune diseases include connective tissues diseases such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis, and dermatomyositis. Rheumatoid arthritis is the most prevalent disease in this group.
The antinuclear antibody (ANA) test is used to screen for connective tissue diseases and other autoimmune diseases by detecting the presence of autoantibodies to specific components of the cell nucleus. An extractable nuclear antigen (ENA) panel may be used as follow up to a positive ANA test to identify the particular cellular component that is causing immunoreactivity and establish the correct diagnosis.1,2,3
As many of the early symptoms of autoimmune conditions (e.g., disabling fatigue, joint pain, skin rash, fever, neurologic signs) are common to other chronic diseases, detection and quantification of ANA can provide pivotal diagnostic information so that appropriate treatment can be initiated to slow or even halt the disease process.4,5
However, serum ANA are detected in up to 18% of the general population and 25% of apparently healthy people, with titers that are higher in women and increase with age.6-9 ANA test results are therefore evaluated carefully in conjunction with clinical signs and symptoms.
- von Muhlen CA, Tan EM. Semin Arthrit Rheum 1995;24(5):323–358.
- Agmon-Levin N, et al. Ann Rheum Dis 2014;73:17–23.
- Chan EKL, et al. Front Immunol 2015;6:Article 112.
- Conrad K, et al. Clinic Rev Allerg Immunol 2016;Jun 28. [Epub ahead of print]
- Mariz HA, et al. Arthritis Rheum 2011;63:191–200.
- Selmi C, et al. Autoimmunity Rev 2016;15:162–166.
- Tan EM, et al. Arthritis Rheum 1997;40(9):1601–1611.
- Peene I, et al. Ann Rheum Dis 2001;60:1131–1136.
- Satoh M, et al. Arthritis Rheum 2012;64:2319–27.
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases, affecting up to 1 in 100 of us as we age.1 It is characterized by chronic inflammation of the joints and progressive destruction of bones and cartilage. Stiff, painful, and swollen joints can significantly impair quality of life. Early diagnosis and treatment is important.
Diagnosis of RA is based primarily on clinical signs and symptoms and the presence of specific autoantibodies in the blood. Detection of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibodies can confirm clinical diagnosis and help in predicting risk of disease development and gauging severity.2,3
Rheumatoid Factor: RF is an autoantibody against the conserved (Fc) portion of immunoglobulin G (IgG). Although it is a widely used serological marker for the diagnosis of RA and present in 60-90% of patients with established RA, RF is only present in about 50% of patients with early-stage RA and it can be detected in patients with other rheumatic disorders.3 RF can also be detected in 5% of healthy individuals, and in 10-30% of the elderly.2
Anti-Cyclic Citrullinated Peptide (CCP) Antibodies: Postranslational modification of the amino acid arginine to citrulline occurs naturally in the body, marking proteins for degradation during cell growth and turnover. While most people can readily clear the citrullinated proteins, those genetically predisposed to RA cannot, leading to the production of autoantibodies and inflammation.2,4 Anti-CCP is a highly specific early marker for RA and a powerful predictor of disease course.2,4,5 Positive anti-CCP results can confirm a diagnosis of RA, especially where RF is negative.6 The antigen used in the Salveo DiagnosticsTM anti-CCP test is the newest, most sensitive, 3rd generation CCP3.1 peptide that detects IgA and IgG antibodies.7 This is the only assay approved by the American Food and Drug Administration (FDA) for the early detection of RA.8
Uric Acid: Uric acid is a byproduct of purine nucleotide metabolism. Excess serum uric acid can cause crystals to form in the joints and other tissues. In genetically predisposed individuals, this may lead to inflammation and gout—a painful, chronic form of arthritis. High uric acid levels are also a risk factor for cardiovascular disease.9
The upregulated immune response–inflammation cycle characteristic of autoimmune diseases can cause chronic tissue damage over time. However, early treatment of RA or gout can alleviate inflammation, slow damage to the joints, and improve clinical outcome.
- Rheumatoid Arthritis Facts and Statistics. Rheumatoid Arthritis Support Network. Last Edited: August 3, 2016. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/
- Taylor P, et al. Autoimmune Dis 2011;815038. (8)
- Sun J, et al. Clin Exp Rheumatol 2014;32:11-21.
- Van Venrooij WJ, et al. Ann NY Acad Sci 2008;1143:268-285.
- Jilani AA, et al. Int J Rheumatol 2015;2015;728610.
- Aletaha D, et al. Arthritis Rheum 2010;62:2569-2581.
- Vos I, et al. Clin Rheumatol 2017;36:1487-1492.
- Infantino M, et al. Clin Chim Acta 2014;436:237-242.
- Singh JA. Ann Rheum Dis 74(4):631-634.
General Immune Function
Immunoglobulins are antibodies; proteins produced by cells of the immune system in response to bacteria, viruses, and other microorganisms or any substance that is recognized by the body as “non-self” and therefore potentially harmful. This test measures the amount of immunoglobulins G, A, M, and E (IgG, IgA, IgM, IgE) in the blood. It provides important information about the health of an individual’s immune system and is used to help diagnose various conditions and diseases that affect the levels of one or more of these Ig classes.